Twenty years ago, Dr. Charles Sawyers played a pivotal role in the development of imatinib (Gleevec®), a game-changing cancer drug that has gone on to save millions of lives and open doors for research and innovation. Gleevec’s astonishing success paved the way for targeted drugs and became the North Star that many researchers followed.
Memorial Sloan Kettering Cancer Center’s Dr. Diane Reidy-Lagunes spoke with Dr. Sawyers for an episode of Cancer Straight Talk from MSK, a podcast that brings together patients and experts to have straightforward evidence-based conversations. They discussed what is next in the field of cancer pharmaceuticals. Is another silver bullet on the horizon?
Listen to the episode or read a transcript:
The Future of Cancer Drugs: A Conversation with Dr. Charles Sawyers
